Litus Therapeutics is developing a novel therapy against TNBC and other solid tumors that beats the prevailing standard of care.
Litus Therapeutics is advancing therapies that target a critical feature of many cancers: silenced tumor suppressor genes. Using a newly developed analog of clofarabine, a cancer drug product previously developed at Southern Research, the team behind Litus has shown it can correct epigenetic dysregulation in cancer cells and promote cancer cell death. Litus expects that these new therapies will be powerful tools in the fight against triple-negative breast cancer as well as other solid and liquid cancers.
Breast cancer is the second most common cancer in American women, after skin cancer, and the most prevalent cancer in the world. Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks estrogen and progesterone receptors and doesn’t make any or too much of the protein called HER2. It accounts for 15–20% of all diagnosed breast cancer cases. TNBC is aggressive and highly metastatic and is more likely to come back after treatment than other types of breast cancer. The majority of TNBC patients have a poor prognosis. More than 50% of patients experience a relapse 3 to 5 years after diagnosis, and the median overall survival (OS) is currently 12-18 months for metastatic TNBC (mTNBC). Litus Therapeutics is working on a novel therapy against TNBC and other solid tumors.